Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd., part of Jiangxi Jemincare Group Co., Ltd., is a Chinese company. The firm develops, manufactures and sells pharmaceutical products.

Using InnoMedica’s patented technology of a highly innovative drug delivery system, active pharmaceutical agents that were previously applied systemically can now be transported selectively to the affected area and released locally. Developing a new generation of medication, for example, cancer can be treated much more effective, while at the same time side effects for patients are reduced to a minimum.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Ortho Biotech Products LP provides innovative products and services which are designed to enhance the lives of individuals with serious chronic illnesses. The company's products include PROCRIT, DOXIL and LEUSTATIN. Ortho Biotech Products was founded in 1990 and is headquartered in Bridgewater, NJ

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

TTY Biopharm Company Limited was established in 1960. For more than fifty years, TTY Biopharm has transformed from a production and sales oriented traditional generic drug pharmaceutical factory into development and marketing of branded generic drugs. With unending self-renovation and transformation, they utilize the experience, technology, and relationship network accumulated over the decades to seek improvement. Nowadays, they redefine ourselves as a biotech company focusing on developing special formulations and new drugs. They hope to achieve our enterprise vision of “improving the quality of human life with scientific innovation.”

DONGKOOK Pharm. Co. Ltd. constructed the prefilled syringe system in its second factory (located at Kwanghyewon-myeon, Jincheon-gun, Chungbuk) for the first time in Asia and produced a large amount of various kinds of ultramodern injection agents. Located on its site are its central research institute, raw material factory, etc. where the raw materials of its main products are extracted and synthesized directly. Also, its third factory completed in 1994 is equipped with ultramodern facilities and is by no means inferior to other factories as the base of a leading company in a new millennium. Particularly, DONGKOOK invests more than 5% of the annual sale for research and development expenses while operating its central research institute centered on holders of master’s degree and PhD.

Sundoc is devoted to preparations for research and development and industrialization. It provides technologies for drug research, development, and production to create newly prepared products with separate intellectual property rights.

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Zhejiang Cancer Hospital is a Chinese private company located in Hangzhou. The firm operates as an cancer hospital.

Claris Lifesciences Limited is a multi-business enterprise and the Holding Company of Claris Injectables - a wholly-owned subsidiary dealing in Specialty Injectables business, collectively ‘Claris’; and Claris Otsuka - a Joint Venture with Japanese Otsuka Pharmaceutical Factory, Inc. & Mitsui & Co. Ltd. for Infusion business in India & Emerging Markets. Coupled with our strength of technical know-how & expertise in manufacturing and marketing injectables products, our growth is catapulted with the support of a team of scientists, pharmaceutical experts, and management professionals, who work diligently to take the organisation to newer heights year-on-year. Claris Injectables Claris manufactures and/or markets products across multiple delivery systems, markets, and therapeutic segments, including anesthesia & analgesics, blood products, anti-infectives, critical care, and nephrology. A significant majority of these products are generic drugs, capable of being directly injected into the human body, predominantly used in the treatment of critical illnesses. The customer base primarily includes government and semi-government institutions, group corporate hospitals, standalone prominent hospitals, and nursing homes. With emphasis on quality, technology, and innovation, we offer a range of niche technology-driven injectables products across delivery systems, such as bags (PVC & NPVC), vials, ampoules, glass bottles, etc.

Shanxi Zhendong Pharmaceutical Co., Ltd. engages in the research and development, manufacture and distribution of Chinese traditional medicines and western medicines. Its products include Yanshu injection, Norfloxacin, Shuxuening injection, Guanxinning injection, Amoxicillin Sodium for injection, Cefathiamidine for injection and Riboflavin Sodium Phosphate for injection. The company was founded on November 22, 1993 and is headquartered in Changzhi, China.